Patents by Inventor Thomas R. Cech

Thomas R. Cech has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for Eliciting an Immune Response to Human Telomerase Reverse Transcriptase
    Publication number: 20160263203
    Abstract: The invention provides compositions and methods related to human telomerase reverse transcriptase (hTRT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.
    Type: Application
    Filed: December 30, 2015
    Publication date: September 15, 2016
    Inventors: THOMAS R. CECH, JOACHIM LINGNER, TORU M. NAKAMURA, KAREN B. CHAPMAN, GREGG B. MORIN, CALVIN B. HARLEY, WILLIAM H. ANDREWS
  • Method for Eliciting an Immune Response to Human Telomerase Reverse Transcriptase
    Publication number: 20150250863
    Abstract: The invention provides compositions and methods related to human telomerase reverse transcriptase (hTRT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.
    Type: Application
    Filed: February 25, 2014
    Publication date: September 10, 2015
    Applicants: The Regents of the University of Colorado, Geron Corporation
    Inventors: Thomas R. Cech, Joachim Lingner, Toru M. Nakamura, Karen B. Chapman, Gregg B. Morin, Calvin B. Harley, William H. Andrews
  • Method for eliciting an immune response to human telomerase reverse transcriptase
    Patent number: 8709995
    Abstract: The invention provides compositions and methods related to human telomerase reverse transcriptase (hTRT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.
    Type: Grant
    Filed: August 20, 2007
    Date of Patent: April 29, 2014
    Assignees: Geron Corporation, The Regents of the University of Colorado
    Inventors: Thomas R. Cech, Joachim Lingner, Toru M. Nakamura, Karen B. Chapman, Gregg B. Morin, Calvin B. Harley, William H. Andrews
  • Human telomerase catalytic subunit
    Patent number: 8236774
    Abstract: The invention provides compositions and methods related to human telomerase reverse transcriptase (hTRT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.
    Type: Grant
    Filed: August 21, 2009
    Date of Patent: August 7, 2012
    Assignee: Geron Corporation
    Inventors: Thomas R. Cech, Joachim Lingner, Toru Nakamura, Karen B. Chapman, Gregg B. Morin, Calvin B. Harley, William H. Andrews
  • Kit for detection of telomerase reverse transcriptase nucleic acids
    Patent number: 8222392
    Abstract: The invention provides compositions and methods related to human telomerase reverse transcriptase (hTRT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.
    Type: Grant
    Filed: August 20, 2007
    Date of Patent: July 17, 2012
    Assignees: Geron Corporation, The Regents of the University of Colorado
    Inventors: Thomas R. Cech, Joachim Lingner, Toru M. Nakamura, Karen B. Chapman, Gregg B. Morin, Calvin B. Harley, William H. Andrews
  • Human Telomerase Catalytic Subunit
    Publication number: 20110318832
    Abstract: The invention provides compositions and methods related to human telomerase reverse transcriptase (hTRT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.
    Type: Application
    Filed: August 21, 2009
    Publication date: December 29, 2011
    Applicant: Geron Corporation
    Inventors: Thomas R. Cech, Joachim Lingner, Toru Nakamura, Karen B. Chapman, Gregg B. Morin, Calvin B. Harley, William H. Andrews
  • Antibody to telomerase reverse transcriptive
    Patent number: 7750121
    Abstract: The invention provides compositions and methods related to human telomerase reverse transcriptase (hTRT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.
    Type: Grant
    Filed: August 17, 2005
    Date of Patent: July 6, 2010
    Assignees: Geron Corporation, The Regents of the University of Colorado
    Inventors: Thomas R. Cech, Joachim Lingner, Toru Nakamura, Karen B. Chapman, Gregg B. Morin, Calvin B. Harley, William H. Andrews
  • Human telomerase reverse transcriptase polypeptides
    Patent number: 7622549
    Abstract: The invention provides compositions and methods related to human telomerase reverse transcriptase (hTRT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.
    Type: Grant
    Filed: June 24, 2004
    Date of Patent: November 24, 2009
    Assignees: Geron Corporation, The Regents of the University of Colorado
    Inventors: Thomas R. Cech, Joachim Lingner, Toru Nakamura, Karen B. Chapman, Gregg B. Morin, Calvin B. Harley, William H. Andrews
  • Kit for detection of telomerase reverse transcriptase nucleic acids
    Publication number: 20090269739
    Abstract: The invention provides compositions and methods related to human telomerase reverse transcriptase (hTRT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.
    Type: Application
    Filed: August 20, 2007
    Publication date: October 29, 2009
    Applicants: Geron Corporation, The Regents of the University of Colorado
    Inventors: Thomas R. Cech, Joachim Lingner, Toru M. Nakamura, Karen B. Chapman, Gregg B. Morin, Calvin B. Harley, William H. Andrews
  • Increasing the proliferative capacity of cells using telomerase reverse transcriptase
    Patent number: 7585622
    Abstract: The invention provides compositions and methods related to human telomerase reverse transcriptase (hTRT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.
    Type: Grant
    Filed: November 2, 1999
    Date of Patent: September 8, 2009
    Assignees: Geron Corporation, The Regents of the University of Colorado
    Inventors: Thomas R. Cech, Joachim Lingner, Toru Nakamura, Karen B. Chapman, Gregg B. Morin, Calvin B. Harley, William H. Andrews
  • Nucleic acid compositions for eliciting an immune response against telomerase reverse transcriptase
    Patent number: 7560437
    Abstract: The present invention is directed to pharmaceutical compositions comprising a telomerase reverse transcriptase polypeptide or a polypeptide homologous to a telomerase reverse transcriptase. The present invention is also directed to pharmaceutical compositions comprising a polynucleotide encoding either of the aforesaid polypeptides. The present invention is further directed to methods for eliciting an immune response to telomerase reverse transcriptase in a subject.
    Type: Grant
    Filed: January 11, 2002
    Date of Patent: July 14, 2009
    Assignees: Geron Corporation, The Regents of the University of Colorado
    Inventors: Thomas R. Cech, Joachim Lingner, Toru Nakamura, Karen B. Chapman, Gregg B. Morin, Calvin B. Harley, William H. Andrews
  • Muteins of human telomerase reverse transcriptase lacking telomerase catalytic activity
    Patent number: 7517971
    Abstract: The invention provides compositions and methods related to human telomerase reverse transcriptase (hTRT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.
    Type: Grant
    Filed: November 22, 2000
    Date of Patent: April 14, 2009
    Assignees: Geron Corporation, The Regents of the University of Colorado
    Inventors: Thomas R. Cech, Joachim Lingner, Toru Nakamura, Karen B. Chapman, Gregg B. Morin, Calvin B. Harley, William H. Andrews
  • Immunogenic composition
    Publication number: 20080279871
    Abstract: The invention provides compositions and methods related to human telomerase reverse transcriptase (hTRT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.
    Type: Application
    Filed: August 20, 2007
    Publication date: November 13, 2008
    Applicants: GERON CORPORATION, UNIVERSITY TECHNOLOGY CORPORATION
    Inventors: Thomas R. Cech, Joachim Lingner, Toru M. Nakamura, Karen B. Chapman, Gregg B. Morin, Calvin B. Harley, William H. Andrews
  • Treating cancer using a telomerase vaccine
    Patent number: 7413864
    Abstract: The invention provides compositions and methods related to human telomerase reverse transcriptase (hTRT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.
    Type: Grant
    Filed: June 24, 2004
    Date of Patent: August 19, 2008
    Assignees: Geron Corporation, The Regents of the University of Colorado
    Inventors: Thomas R. Cech, Joachim Lingner, Toru Nakamura, Karen B. Chapman, Gregg B. Morin, Calvin B. Harley, William H. Andrews
  • Identifying and testing antisense oligonucleotides that inhibit telomerase reverse transcriptase
    Patent number: 7297488
    Abstract: This disclosure provides TRT antisense oligonucleotides, methods of detecting TRT, methods of diagnosing telomerase-related conditions, methods of diagnosing and providing a prognosis for cancer, and methods of treating telomerase-related conditions, including cancer.
    Type: Grant
    Filed: August 8, 2003
    Date of Patent: November 20, 2007
    Assignees: Geron Corporation, The Regents of the University of Colorado
    Inventors: Thomas R. Cech, Joachim Lingner, Toru Nakamura, Karen B. Chapman, Gregg B. Morin, Calvin B. Harley, William H. Andrews
  • Antibody to telomerase reverse transcriptase
    Patent number: 7285639
    Abstract: The present invention is directed to monoclonal or recombinant antibodies or fragments thereof that bind to human telomerase reverse transcriptase (hTRT) protein. The present invention is also directed to methods of identifying or detecting hTRT polypeptides in biological samples. The invention is further directed to methods of generating antibodies that specifically bind to hTRT protein.
    Type: Grant
    Filed: January 18, 2002
    Date of Patent: October 23, 2007
    Assignees: Geron Corporation, The Regents of the University of Colorado
    Inventors: Thomas R. Cech, Joachim Lingner, Toru Nakamura, Karen B. Chapman, Gregg B. Morin, Calvin B. Harley, William H. Andrews
  • Nucleic acids encoding human telomerase reverse transcriptase and related homologs
    Patent number: 7262288
    Abstract: The invention provides compositions and methods related to human telomerase reverse transcriptase (hTRT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.
    Type: Grant
    Filed: November 22, 2000
    Date of Patent: August 28, 2007
    Assignees: Geron Corporation, The Regents of the University of Colorado
    Inventors: Thomas R. Cech, Joachim Lingner, Toru Nakamura, Karen B. Chapman, Gregg B. Morin, Calvin B. Harley, William H. Andrews
  • Mammalian cells that have increased proliferative capacity
    Patent number: 7195911
    Abstract: The present invention is directed to cells comprising a recombinant polynucleotide sequence that encodes a telomerase reverse transcriptase protein, variant, or fragment having telomerase catalytic activity when complexed with a telomerase RNA.
    Type: Grant
    Filed: January 11, 2002
    Date of Patent: March 27, 2007
    Assignees: Geron Corporation, The Regents of the University of Colorado
    Inventors: Thomas R. Cech, Joachim Lingner, Toru Nakamura, Karen B. Chapman, Gregg B. Morin, Calvin B. Harley, William H. Andrews
  • Telomerase
    Patent number: 7056513
    Abstract: The present invention is directed to novel telomerase nucleic acids and amino acids. In particular, the present invention is directed to nucleic acid and amino acid sequences encoding various telomerase protein subunits and motifs, including the 123 kDa and 43 kDa telomerase protein subunits of Euplotes aediculatus, and related sequences from Schizosaccharomyces, Saccharomyces sequences, and human telomerase. The present invention is also directed to polypeptides comprising these telomerase protein subunits, as well as functional polypeptides and ribonucleoproteins that contain these subunits.
    Type: Grant
    Filed: April 26, 2001
    Date of Patent: June 6, 2006
    Assignees: Geron Corporation, Regents of the University of Colorado
    Inventors: Thomas R. Cech, Joachim Lingner, Toru Nakamura, Karen B. Chapman, Gregg B. Morin, Calvin B. Harley, William H. Andrews
  • Alteration of sequence of a target molecule
    Patent number: 7045293
    Abstract: Method for splicing a target nucleic acid molecule with a separate nucleic acid molecule. Such splicing generally causes production of a chimeric protein with advantageous features over that protein naturally produced from the target nucleic acid prior to splicing. The method includes contacting the target nucleic acid molecule with a catalytic nucleic acid molecule including the separate nucleic acid molecule. Such contacting is performed under conditions in which at least a portion of the separate nucleic acid molecule is spliced with at least a portion of the target nucleic acid molecule to form a chimeric nucleic acid molecule. In this method, the catalytic nucleic molecule is chosen so that it is not naturally associated with the separate nucleic acid molecule.
    Type: Grant
    Filed: March 12, 2004
    Date of Patent: May 16, 2006
    Assignee: The Regents of the University of Colorado
    Inventors: Bruce Sullenger, Thomas R. Cech